Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BI 1703880 |
| Trade Name | |
| Synonyms | BI-1703880|BI1703880 |
| Drug Descriptions |
BI 1703880 acts as a STING agonist, potentially resulting in increased type 1 interferon response and cytokine release (Journal for ImmunoTherapy of Cancer 2022;10, Suppl_2, 626). |
| DrugClasses | STING1 Agonist 21 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BI 1703880 | BI 1703880 | 0 | 0 |
| BI 1703880 + Ezabenlimab | BI 1703880 Ezabenlimab | 0 | 1 |